Aura Biosciences, Inc.
AURAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 11, 2026 | H.C. Wainwright | $18.00(+126%) | $7.98 | TheFly | |
| May 12, 2026 | Leerink Partners | $17.00(+115%) | $7.90 | TheFly | |
| Mar 26, 2025 | JMP Securities | Jonathan Wolleben | $19.00(+217%) | $5.99 | TheFly |
| Mar 25, 2025 | H.C. Wainwright | Edward White | $25.00(+253%) | $7.08 | TheFly |
| Oct 18, 2024 | Scotiabank | George Farmer | $23.00(+124%) | $10.29 | StreetInsider |
| Oct 18, 2024 | H.C. Wainwright | Ed White II | $22.00(+114%) | $10.29 | StreetInsider |
| Oct 18, 2024 | BTIG | Julian Harrison | $24.00(+133%) | $10.29 | StreetInsider |
| Jul 25, 2024 | H.C. Wainwright | Edward White | $21.00(+127%) | $9.27 | TheFly |
| Nov 11, 2022 | JMP Securities | $30.00(+132%) | $12.95 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 29, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 30, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 13, 2025 |
| JMP Securities | maintain | Market Outperform | May 23, 2025 |
| JMP Securities | maintain | Market Outperform | Mar 26, 2025 |
| Citizens Capital Markets | maintain | Market Outperform | Mar 26, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 24, 2025 |
| JMP Securities | maintain | Market Outperform | Dec 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2024 |
| BTIG | maintain | Buy | Oct 18, 2024 |
| Scotiabank | maintain | Sector Outperform | Oct 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 13, 2024 |
| JMP Securities | maintain | Market Outperform | Sep 13, 2024 |
| JMP Securities | maintain | Market Outperform | Aug 28, 2024 |
| BTIG | maintain | Buy | Dec 8, 2023 |
| JMP Securities | maintain | Market Outperform | Nov 10, 2023 |
| JMP Securities | maintain | Outperform | Mar 16, 2023 |
| JMP Securities | maintain | Market Outperform | Nov 11, 2022 |
| JMP Securities | maintain | Market Outperform →Outperform | Jul 19, 2022 |
| Cowen & Co. | maintain | Outperform | Nov 23, 2021 |
| Evercore ISI Group | maintain | Outperform | Nov 23, 2021 |
| BTIG | maintain | Buy | Nov 23, 2021 |
Earnings History
Next report: Mar 30, 2027 · EPS est. $-0.35| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.48 | $-0.38 | — | — |
| May 11, 2026 | $-0.50 | $-0.40 | — | — |
| Mar 30, 2026 | $-0.37 | $-0.43 | — | — |
| Nov 13, 2025 | $-0.40 | $-0.46 | — | — |
| Aug 13, 2025 | $-0.47 | $-0.49 | — | — |
| May 15, 2025 | $-0.55 | $-0.47 | — | — |
| Mar 24, 2025 | $-0.52 | $-0.43 | — | — |
| Nov 12, 2024 | $-0.42 | $-0.44 | — | — |
News
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026. Fireside chat at 2:40 p.m.
Aura Biosciences offers a de-risked, fully funded play on the bel-sar for early choroidal melanoma, with pivotal Phase 3 data expected in 2027. AURA's cash position of $323.8 million as of June 2026 supports operations into 1H 2029, eliminating near-term financing risk ahead of its binary readout. Strategic refocus on ocular oncology, leadership overhaul, and workforce reduction streamline execution and concentrate resources on a largely uncontested market.
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Frazier Life Sciences Management L.P. grew its position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) by 39.2% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,100,000 shares of the company's stock after purchasing an additional 2,000,000 shares during the quarter. Aura
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.
BlackRock Inc. bought a new stake in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,707,674 shares of the company's stock, valued at approximately $33,424,000. BlackRock Inc. owned approximately 4.55% of
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura's new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura's new Chief Operating Officer, and Julie Person, Aura's new C…
ADAR1 Capital Management LLC bought a new position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 130,152 shares of the company's stock, valued at approximately $924,000. ADAR1 Capital Management LLC
Aura Biosciences, Inc. is focused on late-stage development of Bel-sar for early choroidal melanoma, addressing significant unmet medical needs. The Phase 3 CoMpass trial is fully enrolled, with topline data expected in 2H 2027; Phase 2 data showed 80% tumor control and strong safety. A recent C-suite overhaul and $299M capital raise position AURA to prioritize ocular oncology and streamline operations, with funding expected to last into 2029.